Category NEWS

Pyxis

Pyxis, Principia, and CommodityAI Partner on Agentic AI for Commodities

Pyxis Group, Principia Consulting, and CommodityAI Partner to Bring Agentic AI to Commodity Operations Pyxis Group, a global advisory firm serving the commodities industry, together with its joint venture partner Principia Consulting, announced a strategic partnership with CommodityAI, the agentic…

Read MorePyxis, Principia, and CommodityAI Partner on Agentic AI for Commodities
Scientist.com

Scientist.com Unveils Unified Innovation Hub® to Integrate Scientific Insights with Its Award-Winning R&D Platform

Scientist.com Launches Unified Innovation Hub®, Connecting Scientific Thought Leadership with its Award-Winning R&D Orchestration Platform New public resource hub brings together technical webinars, expert insights, podcasts and industry thought leadership across the life science ecosystem Scientist.com, the life science industry’s…

Read MoreScientist.com Unveils Unified Innovation Hub® to Integrate Scientific Insights with Its Award-Winning R&D Platform
Snke and Precision NeuroMed Partner to Accelerate Learning

Snke and Precision NeuroMed Join Forces to Accelerate Precision Brain Therapy Development

Snke and Precision NeuroMed Partner to Accelerate Learning Cycles in Precision Brain Therapies Snke, a pioneering health tech company, and Precision NeuroMed (PNM), a clinical-stage biotechnology company advancing precision therapeutics for central nervous system (CNS) diseases, announced a partnership to streamline and…

Read MoreSnke and Precision NeuroMed Join Forces to Accelerate Precision Brain Therapy Development
insitro Presents New Data

insitro Presents New Data on AI-Discovered MASH Candidate at ADA 2026

insitro Presents New Data Demonstrating Its AI-Discovered MASH Candidate Shows Anti-Fibrotic Signal Beyond Liver-Fat Reduction at the American Diabetes Association 86th Scientific Sessions insitro, the physical AI company unlocking causal human biology, presented new preclinical data from its metabolic dysfunction-associated…

Read Moreinsitro Presents New Data on AI-Discovered MASH Candidate at ADA 2026
Adaptyx Biosciences

Adaptyx Biosciences Presents First Human Continuous Free Cortisol Data at ADA

Adaptyx Biosciences Showcases Breakthrough First-in-Human Continuous Free Cortisol Monitoring at ADA, Revealing Real-Time Hormonal Dynamics Linked to Metabolic, Cardiovascular, Stress, and Sleep Health Adaptyx Biosciences, a Stanford University spinout commercializing more than 18 years of continuous molecular biosensing research, presented…

Read MoreAdaptyx Biosciences Presents First Human Continuous Free Cortisol Data at ADA
Tidepool Presents

Tidepool Presents New Clinical Data and Women’s Health Initiative at ADA 2026

Tidepool Showcases New Real-World Clinical Data and Landmark Women’s Health Initiative at ADA 2026 Tidepool, the nonprofit leader advancing innovation in diabetes technology, today unveiled new clinical insights and research initiatives in conjunction with the American Diabetes Association’s (ADA) 86th…

Read MoreTidepool Presents New Clinical Data and Women’s Health Initiative at ADA 2026
Sasol

Sasol Invests €60M in Brunsbüttel to Expand Advanced Materials and Specialty Chemicals

Sasol Advances Strategic Growth in Advanced Materials and Specialty Chemicals with €60 Million Brunsbüttel Investment Sasol International Chemicals announced a €60 million investment at its Brunsbüttel site to expand its advanced materials and specialty chemicals capabilities, reinforcing the company’s position…

Read MoreSasol Invests €60M in Brunsbüttel to Expand Advanced Materials and Specialty Chemicals
Onchilles Pharma Begins Phase 12 Trial of

Onchilles Pharma Begins Phase 1/2 Trial of N17350, Dosing First Patient with Advanced Solid Tumors

Onchilles Pharma Doses First Patient in Phase 1/2 Clinical Trial of N17350 for Advanced Solid Tumors Onchilles Pharma, a clinical-stage biotechnology company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced that the first patient has been dosed…

Read MoreOnchilles Pharma Begins Phase 1/2 Trial of N17350, Dosing First Patient with Advanced Solid Tumors